Inflammatory myopathy

G6_INFLAMYOP

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519972
1. Apply sex-specific rule None	519972
2. Check conditions None	519972
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — G72.4 Cause of death: ICD-10 — G72.4 2 out of 7 registries used, show all original rules.	57
4. Check minimum number of events None	57
5. Include endpoints None	57
6. Filter based on genotype QC (FinnGen only)	57

Control definitions (FinnGen only)

Control exclude: G6_MYONEU

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: G72
Name in latin: Myopathia inflammatoria non alibi classificata

NAME	G6_INFLAMYOP
CONTROL_EXCLUDE	G6_MYONEU
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	G724
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	G724
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Inflammatory myopathy based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	383	177	205
Only index persons	356	166	190
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	72.29	72.78	71.86
Only index persons	72.51	73.14	71.96

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	57	28	29
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	74.97	74.25	75.66

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
57: Matched controls
570

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

G72.4

ICD-10 Finland

Inflammatory myopathy, not elsewhere classified

+∞

78.9

M60.8

ICD-10 Finland

Other myositis

432.0

27.1

G72.9

ICD-10 Finland

Myopathy, unspecified

+∞

19.9

R13

ICD-10 Finland

Dysphagia

11.8

18.1

M60.9

ICD-10 Finland

Myositis, unspecified

217.3

16.4

JC2KB

NOMESCO Finland

Functional X-ray examination of swallowing

199.0

15.3

G72.8

ICD-10 Finland

Other specified myopathies

199.0

15.3

NXL00

NOMESCO Finland

Biopsy of muscle

+∞

13.0

L28

ICPC

Limited function/disability (L)

6.8

12.0

JDB10

NOMESCO Finland

Percutaneous gastrostomy

119.0

9.7

SPAT1229

SPAT

Assessment of need for aid

8.9

8.7

M33.2

ICD-10 Finland

Polymyositis

104.9

8.7

J69.0

ICD-10 Finland

Pneumonitis due to food and vomit

26.7

8.4

JCA55

NOMESCO Finland

Endoscopic dilatation of oesophagus

52.5

8.0

L19

ICPC

Muscle symptom/complaint NOS

29.7

7.9

NJ3CG

NOMESCO Finland

Extensive MRI examination of extremities with median high magnet

+∞

7.4

SPAT1230

SPAT

Aid fitting and borrowing and monitoring of use

4.8

7.4

N28

ICPC

Limited function/disability (N)

34.9

7.4

GD1QA

NOMESCO Finland

Supine thorax X-ray examination

4.5

6.9

504

Kela drug reimbursment

Conditions requiring daily forced enteral nutrition

26.2

6.9

TJD20

NOMESCO Finland

Change of gastrostomy tube

+∞

6.4

K22.4

ICD-10 Finland

Dyskinesia of oesophagus

+∞

6.4

ZXD05

NOMESCO Finland

Urgent procedure

4.1

6.3

103

SPAT1215

SPAT

Assessment of need for medical rehabilitation

9.8

6.2

N18

ICPC

Paralysis/weakness

13.1

6.1

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(4035726) Immunohistochemistry procedure

7.40

12.03

1.3

1.2

—

(3019225) pH of Specimen

5.52

7.47

3.6

5.5

—

(3022313) Gas panel - Capillary blood

8.79

5.44

3.5

7.3

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

7.68

5.42

1.7

1.6

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

6.93

5.09

1.7

1.9

—

(40760892) CBC W Ordered Manual Differential panel - Blood

205

3.56

4.95

10.2

5.8

—

(3013512) EKG study

141

3.38

4.87

5.1

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

3.31

4.11

2.3

1.8

—

(3019309) Folate [Moles/volume] in Red Blood Cells

120

2.93

3.72

2.7

1.7

1228.79

1296.03

nmol/l

0.12

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

7.79

3.47

2.0

1.5

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

5.41

3.40

1.4

1.2

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

237

2.81

3.33

9.0

8.2

1.22

mmol/l

0.04

198

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

222

2.69

3.17

9.5

7.1

1.21

mmol/l

0.09

191

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

164

2.56

3.01

3.9

3.5

1207.38

1792.86

ng/l

0.58

136

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

124

2.62

2.99

1.9

1.7

416.83

457.18

pmol/l

0.33

102

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

4.10

2.95

1.9

1.4

—

(3023368) Bacteria identified in Blood by Culture

143

2.50

2.82

5.8

4.5

—

(3042631) Mycobacterium sp identified in Specimen

8.97

2.80

3.4

1.5

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

120

2.54

2.78

2.8

1.9

3.22

2.79

mg/l

0.31

105

(3022217) INR in Platelet poor plasma by Coagulation assay

232

2.50

2.75

16.8

14.1

1.28

1.26

inr

0.04

(3027315) Oxygen [Partial pressure] in Blood

7.68

2.60

3.2

3.6

7.92

8.07

kpa

—

(3013290) Carbon dioxide [Partial pressure] in Blood

7.68

2.60

3.2

3.6

5.40

5.10

kpa

—

(3037467) Urinalysis macro (dipstick) panel - Urine

319

2.66

2.50

5.8

4.8

—

(3004616) Nuclear Ab [Presence] in Serum

6.71

2.42

1.2

1.1

—

(3007853) Bacteria identified in Skin by Aerobe culture

2.71

2.24

1.7

1.6

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

210

2.19

2.17

2.7

2.5

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

116

2.28

2.17

2.3

2.9

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

4.34

2.10

1.7

1.1

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.04

2.04

1.9

2.0

—

(40768804) Tissue Pathology biopsy report

178

2.13

2.02

2.1

2.0

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

4.86

1.98

1.0

1.5

—

(3013707) Erythrocyte sedimentation rate by Westergren method

337

2.34

1.93

7.2

4.0

20.73

13.96

mm/h

1.45

297

(3005719) IgG [Mass/volume] in Serum or Plasma

2.83

1.73

3.4

2.1

12.04

9.34

g/l

—

(40768797) Stomach Pathology biopsy report

2.35

1.63

1.2

1.3

—

(3030467) Casts [#/volume] in Urine by Automated count

138

1.97

1.57

3.0

3.1

0.52

0.18

e6/l

0.57

106

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

173

1.92

1.57

3.1

3.2

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.62

1.54

1.3

2.4

—

(36304419) Bacteria [Presence] in Urine

131

1.95

1.52

2.9

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

2.79

1.40

1.3

1.9

—

(3042936) Bacteria identified in Isolate by Culture

2.18

1.40

4.4

2.1

—

(3002256) Pathology report gross observation

2.26

1.31

1.1

1.2

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

2.56

1.28

1.5

2.0

—

(40761536) Microorganisms panel - Urine sediment

2.22

1.21

4.1

4.5

—

(3007164) IgA [Mass/volume] in Serum or Plasma

1.88

1.15

1.7

1.4

3.44

2.19

g/l

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

2.51

1.11

1.8

5.0

25.58

24.17

mmol/l

—

(3003338) MCHC [Mass/volume]

344

0.59

1.11

36.0

21.5

328.37

331.72

g/l

1.15

344

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.13

1.10

1.9

1.4

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

202

1.64

1.00

2.3

2.0

91.04

85.33

pmol/l

0.29

(3044640) Blood type and Crossmatch panel - Blood

156

1.67

0.99

2.6

2.7

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.99

0.99

5.8

3.2

—

(3041096) Erythrocytes [Presence] in Urine by Automated

130

1.69

0.98

4.3

4.0

—

(3018095) Leukocytes [#/volume] in Urine

176

1.63

0.95

3.3

3.8

65.83

105.97

e6/l

0.35

131

(3009508) Creatinine [Moles/volume] in Urine

149

1.65

0.94

2.3

3.2

6.71

6.94

mmol/l

0.06

120

(3012516) Albumin [Mass/volume] in Urine

142

1.63

0.89

2.4

3.3

106.54

506.78

mg/l

0.42

(3011397) Hemoglobin [Presence] in Urine by Test strip

105

0.52

0.83

2.0

3.6

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.84

0.82

1.8

—

(40761511) CBC panel - Blood by Automated count

454

1.82

0.79

32.4

15.1

—

(3020682) Albumin/Creatinine [Ratio] in Urine

155

1.56

0.78

3.0

4.0

18.81

7.31

mg/mmol

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.75

0.78

2.8

1.8

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.75

0.78

2.8

1.8

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

417

1.72

0.77

22.5

16.2

89.65

73.87

ml/min/173m2

3.07

326

(3020564) Creatinine [Moles/volume] in Serum or Plasma

467

1.87

0.70

28.6

19.3

68.78

83.66

umol/l

1.09

467

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

1.93

0.70

4.4

9.2

28.34

24.80

mmol/l

—

(3036481) Cortisol [Moles/volume] in Serum or Plasma

1.67

0.68

3.7

1.8

274.57

402.14

nmol/l

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

422

1.65

0.66

4.5

5.0

4.25

4.46

mmol/l

0.67

378

(3044889) 12 lead EKG panel

324

0.68

0.66

4.9

4.1

—

(36660697) Celiac disease serology panel - Serum

1.79

0.65

1.0

1.1

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.59

0.61

2.0

1.5

—

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

414

1.58

0.61

5.0

4.7

1.87

2.02

mu/l

0.50

357

(3021589) Normoblasts [#/volume] in Blood

182

1.44

0.60

19.7

10.3

0.00

e9/l

0.50

145

(3022621) pH of Urine by Test strip

1.80

0.60

4.2

2.7

—

(3025941) Bacteria identified in Stool by Culture

0.00

0.59

0.0

1.4

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

404

1.54

0.59

4.6

4.4

1.38

1.23

mmol/l

0.94

351

(3022145) Colonoscopy Study observation

1.65

0.56

1.2

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

420

1.49

0.50

4.8

4.9

1.39

1.49

mmol/l

0.82

367

(3021447) Carbon dioxide [Partial pressure] in Venous blood

1.52

0.49

2.1

5.9

6.80

5.77

kpa

—

(3035350) Ketones [Presence] in Urine by Test strip

228

1.35

0.46

3.5

4.1

0.00

estimate

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

434

1.47

0.44

6.0

5.2

6.03

6.01

mmol/l

0.03

380

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.67

0.44

2.6

1.5

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

220

1.33

0.43

4.0

2.9

—

(3002385) Erythrocyte distribution width [Ratio]

369

0.75

0.42

33.8

19.1

17.05

15.19

0.79

363

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.42

0.0

1.1

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.51

0.41

1.6

1.3

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.41

0.0

1.5

—

(3009261) Glucose [Presence] in Urine by Test strip

231

1.32

0.41

4.1

0.00

estimate

—

(3026008) Bacteria identified in Urine by Culture

174

1.33

0.39

3.3

—

(3000991) Gas panel - Venous blood

1.48

0.37

5.7

13.0

—

(3019060) Gas panel - Arterial blood

1.48

0.37

15.8

3.6

—

(3018418) pH of Serum or Plasma

149

1.30

0.33

6.9

4.9

7.41

7.40

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

441

1.37

0.32

5.1

5.6

2.51

2.56

mmol/l

0.14

385

(3021601) Nitrite [Presence] in Urine by Test strip

227

1.27

0.32

5.3

5.7

0.00

estimate

—

(3015736) pH of Urine

179

1.27

0.31

3.3

3.9

—

5.72

—

(1761868) Lipid panel - Serum or Plasma

115

0.74

0.31

2.4

3.3

—

(40758558) Short blood count panel - Blood

115

1.29

0.27

9.0

6.4

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.38

0.24

1.2

1.7

—

(3024354) Oxygen [Partial pressure] in Venous blood

1.21

0.22

2.6

4.0

5.74

3.90

kpa

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

174

0.81

0.21

6.8

5.7

2.05

2.32

ug/l

0.18

150

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.21

0.0

1.3

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

0.00

0.21

0.0

1.1

—

(42529406) Shigella sp [Presence] in Stool by Culture

0.00

0.21

0.0

1.1

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

0.00

0.21

0.0

1.1

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.21

0.0

1.1

—

(1002224) Polysomnography panel

0.00

0.21

0.0

1.1

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

0.21

0.0

1.3

—

(40768793) Breast Pathology biopsy report

0.00

0.21

0.0

1.3

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

4.6

—

86.40

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.21

0.0

1.3

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.21

0.0

1.1

—

(3003181) Sodium [Moles/volume] in Urine

0.00

0.21

0.0

1.5

—

62.38

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.21

0.0

3.1

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

177

1.20

0.20

4.8

4.4

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.15

0.18

16.1

8.4

—

(3000494) Fungus identified in Specimen by Culture

1.06

0.09

4.7

1.5

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

132

0.88

0.07

4.5

5.1

25.12

22.27

—

(3029937) Albumin [Presence] in Urine by Test strip

130

1.10

0.05

3.3

4.2

0.00

estimate

—

(3003694) ABO and Rh group [Type] in Blood

108

1.02

0.00

1.7

1.3

—

(4281824) Cell count and differential, peritoneal fluid

0.00

0.0

1.0

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.0

1.4

—

(3051593) INR in Capillary blood by Coagulation assay

0.00

0.0

11.7

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

4.5

—

4.50

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.0

1.2

—

(42870308) Desmosome IgG Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.3

—

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

0.00

0.0

3.8

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.0

1.2

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.0

1.8

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.2

—

(3000034) Microalbumin [Mass/volume] in Urine

0.00

0.0

4.3

—

42.03

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.2

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.0

1.2

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.2

—

(3010838) Calcium [Moles/time] in 24 hour Urine

0.00

0.0

1.7

—

4.89

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.0

1.2

—

(42870365) C reactive protein [Mass/volume] in Blood by High sensitivity method

0.00

0.0

1.2

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.0

1.2

—

(40760847) Basement membrane Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.3

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

0.00

-0.00

0.0

1.0

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

0.00

-0.00

0.0

1.4

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

-0.00

0.0

3.1

—

52.78

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

-0.00

0.0

1.1

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

0.93

-0.00

5.5

8.7

103.67

103.42

mmol/l

—

(40768795) Lymph node Pathology biopsy report

0.00

-0.00

0.0

1.1

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

0.00

-0.00

0.0

1.1

—

(3011363) Streptococcus pneumoniae Ag [Presence] in Urine

0.00

-0.00

0.0

1.0

—

(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3008898) HLA-B27 [Presence]

0.00

-0.00

0.0

1.1

—

(21494434) Karyotype in Bone marrow

0.00

-0.00

0.0

1.0

—

(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

2.1

—

14.54

—

(3000093) Morphology [Interpretation] in Blood Narrative

0.00

-0.00

0.0

1.0

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

-0.00

0.0

1.3

—

(3020491) Glucose [Moles/volume] in Blood

0.00

-0.00

0.0

1.4

—

7.04

—

(3035320) C reactive protein [Mass/volume] in Body fluid

0.00

-0.00

0.0

2.4

—

Mortality – FinRegistry

↥

Association

Association between endpoint G6_INFLAMYOP and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have G6_INFLAMYOP.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: G6_INFLAMYOP – Inflammatory myopathy

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Inflammatory myopathy

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints